A drug for people with type 2 diabetes may reduce the occurrence of acute graft vs. host disease in patients who received peripheral blood stem cell transplants.
The immune dysfunction can affect between 34% and 51% of transplant patients and is one of the major complications for patients weeks after a transplant, limiting the effectiveness of a cure for leukemia and lymphoma.
A preliminary clinical study at the Indiana University School of Medicine showed 78% of the patients in the study of the drug sitagliptin did not develop the disease, and none of them died.
Building a Workforce to Save Lives.Can your job save a life? Ours do. Learn more about BBG's current job openings and our employee benefit package.
Building Connections to Save Lives.QualTex Laboratories is the largest, independent, non-profit testing laboratory in the United States that offers testing services for global biotechnology customers.
Building Connections to Save Lives.South Texas Blood & Tissue Center supplies blood and blood components to area hospital patients.
